𝔖 Bobbio Scriptorium

✦ LIBER ✦

Minimal Adverse Events in HeartMate II Patients with No Antiplatelet Therapy: Preliminary Results from the European TRACE Study

✍ Scribed by Netuka, I.; Litzler, P.Y.; Berchtold-Herz, M.; Flecher, E.; Zimpfer, D.; Damme, L.; Sundareswaran, K.S.; Farrar, D.J.; Schmitto, J.D.

Book ID: 122245728
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 76 KB
Volume: 33
Category: Article
ISSN: 1557-3117
DOI: 10.1016/j.healun.2014.01.055

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Can Persistent Bleeding in HeartMate II

Can Persistent Bleeding in HeartMate II Patients Be Safely Managed with Reduced Anti-thrombotic Regimens? Preliminary Results from the US-TRACE Study

✍ Katz, J.N.; Adamson, R.; John, R.; Tatooles, A.; Sundareswaran, K.; Kallel, F.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 148 KB

379 Early Results from the SoundMate Stu

379 Early Results from the SoundMate Study. Acoustic Analysis of a Thromboembolic Event in a Patient Treated with HeartMate II™, Mechanical Circulatory Support

✍ L. Hubbert; U.P. Jorde; B. Peterzén; H. Granfeldt; B. Kornhall; K. Morrison; H. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 311 KB

A Randomized, Double-Blind, Multicenter

A Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions: Results From the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) Trial

✍ Seung-Whan Lee; Seong-Wook Park; Young-Hak Kim; Sung-Cheol Yun; Duk-Woo Park; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 653 KB

Adding arabinosylcytosine to idarubicin

Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia: Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study. LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141–6.

✍ Elihu Estey; Miguel A. Sanz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 77 KB